Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2022

Aug 05, 2022

SELL
$31.71 - $43.0 $434,427 - $589,100
-13,700 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$29.88 - $37.04 $110,556 - $137,048
3,700 Added 37.0%
13,700 $1,000
Q4 2021

Feb 14, 2022

SELL
$25.61 - $35.1 $120,367 - $164,970
-4,700 Reduced 31.97%
10,000 $1,000
Q3 2021

Nov 12, 2021

SELL
$33.54 - $40.55 $858,624 - $1.04 Million
-25,600 Reduced 63.52%
14,700 $13,000
Q1 2021

May 04, 2021

BUY
$42.51 - $63.78 $1.71 Million - $2.57 Million
40,300 New
40,300 $33,000
Q4 2020

Feb 08, 2021

SELL
$45.3 - $60.27 $747,450 - $994,455
-16,500 Closed
0 $0
Q3 2020

Nov 03, 2020

BUY
$47.45 - $62.95 $688,025 - $912,775
14,500 Added 725.0%
16,500 $16,000
Q1 2020

May 11, 2020

BUY
$41.6 - $63.4 $83,200 - $126,800
2,000 New
2,000 $13,000

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $5.02B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Cowen And Company, LLC Portfolio

Follow Cowen And Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cowen And Company, LLC with notifications on news.